Kalaris Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell KLRS and other ETFs, options, and stocks.About KLRS
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases.
KLRS Key Statistics
Stock Snapshot
With a market cap of 89.22M, Kalaris Therapeutics(KLRS) trades at $3.73. The stock has a price-to-earnings ratio of -1.75.
As of 2026-07-25, Kalaris Therapeutics(KLRS) stock has fluctuated between $3.52 and $3.89. The current price stands at $3.73, placing the stock +6.0% above today's low and -4.1% off the high.
The Kalaris Therapeutics(KLRS)'s current trading volume is 156.93K, compared to an average daily volume of 1.25M.
During the past year, Kalaris Therapeutics(KLRS) stock moved between $2.14 at its lowest and $11.88 at its peak.
During the past year, Kalaris Therapeutics(KLRS) stock moved between $2.14 at its lowest and $11.88 at its peak.
KLRS News
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...
Kalaris Therapeutics (KLRS) announced the appointment of Liisa Bayko as CFO. She most recently served as managing director and senior biotechnology analyst at E...
Judah Frommer, an analyst from Morgan Stanley, maintained the Buy rating on Kalaris Therapeutics. The associated price target remains the same with $14.00. Clai...
Analyst ratings
88%
of 8 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.